Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article is for informational purposes only. It is not medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before changing your diet, exercise, or supplement regimen.

In March 2024, Kobayashi Pharmaceutical (小林製薬) issued a voluntary recall of a line of red yeast rice dietary supplements after consumers in Japan reported kidney damage following use of the products. By the time the Consumer Affairs Agency (消費者庁) launched a formal investigation, thousands of consumer health reports had accumulated and some deaths had been attributed — provisionally — to product use. The story reached international coverage quickly, and it raised questions that wellness writing about beni-koji had not previously needed to answer: what does this fermented rice actually contain, how do safety profiles differ between products, and is there a meaningful distinction between supplement-form extracts and the traditional fermented food?

The answer matters because the conflation of those two things in the international coverage was not accurate. Beni-koji (紅麹) has been used in Okinawan cuisine, Chinese cooking, and East Asian fermented food traditions for well over a thousand years — as a colorant in festive rice, as a curing agent in fermented tofuyo, as a flavor element in certain sake preparations and braised meat dishes. The concentrated supplement extract in the recalled products represents a different exposure context, a different monacolin K dose, and a different secondary metabolite risk than any of those food applications. What went wrong with the Kobayashi product, and what the mechanism behind its active compounds is, are questions worth separating from whether you can eat tofuyo.

What Monascus purpureus is and how it differs from koji

Beni-koji is produced by fermenting steamed rice with Monascus purpureus, a red-pigmented mold in the family Monascaceae. The generic Japanese term “koji” (麹) refers to any mold-fermented grain culture — which is why both beni-koji and standard rice koji carry the koji name. But the organisms are biologically distinct and produce fundamentally different biochemical outputs.

Aspergillus oryzae — the organism behind miso, soy sauce, sake, and shio koji — primarily produces amylases and proteases: the enzyme classes that drive starch saccharification and protein breakdown in Japan’s main fermented food cluster. Its biology is covered in the koji and fermentation foundation article. Monascus purpureus produces characteristic red-to-orange pigments (ankaflavin, monascorubin, and related azaphilone compounds) alongside a family of polyketide secondary metabolites called monacolins, of which monacolin K is the most pharmacologically significant. The two organisms share a name in common usage but not a chemistry, and not a safety profile.

The HMG-CoA reductase connection

Monacolin K is structurally and functionally identical to lovastatin — the prescription statin first isolated from Aspergillus terreus fermentation and approved by the US FDA in 1987 as the first commercially available HMG-CoA reductase inhibitor. The mechanism is not analogous to statin pharmacology. It is the same pharmacology, via the same compound.

HMG-CoA reductase (3-hydroxy-3-methylglutaryl-CoA reductase) catalyzes an early committed step in the mevalonate pathway — the biochemical route through which cells produce cholesterol from acetyl-CoA. Statins, including lovastatin and monacolin K, inhibit this enzyme competitively. The liver responds by upregulating LDL receptor expression, increasing clearance of LDL particles from the circulation. The LDL marker changes associated with red yeast rice extracts in clinical trials occur through this mechanism, not through some distinct or gentler nutritional pathway.

Multiple randomized controlled trials and subsequent meta-analyses — primarily conducted in Chinese hypercholesterolemic populations — found associations between standardized red yeast rice extract consumption and reductions in LDL cholesterol markers described in the range of 10–25% from baseline, at daily doses providing several milligrams of monacolin K. The effect tracks monacolin K content across trials. This has a direct implication for understanding the risk profile: if the active compound is lovastatin, the side effect profile is also that of lovastatin, including myopathy risk, elevated liver enzyme associations, and drug interactions involving CYP3A4-metabolized medications.

Citrinin: why the risk varies between products

Monascus purpureus can produce citrinin — a polyketide mycotoxin with nephrotoxic properties in animal studies and mutagenic activity in cell culture assays — as a secondary metabolite under certain fermentation conditions. In animal feeding studies, citrinin is associated with proximal renal tubule damage above threshold concentrations; its effects in humans at lower dietary exposure levels are less completely characterized.

The critical interpretive point is that citrinin production is not a fixed property of all Monascus fermentation. It is strain-dependent and fermentation-condition-dependent. Specific Monascus strains exist that produce no detectable citrinin under standard production conditions. Appropriate strain selection and fermentation process monitoring can eliminate it. Independent testing of commercial red yeast rice products — conducted by food science laboratories and regulatory bodies across Europe and Japan — has found substantial variation between brands: some products below detection limits for citrinin, others at concentrations raising safety concerns.

The European Food Safety Authority evaluated citrinin risk in food supplements in its 2012 scientific opinion and established a tolerable daily intake. Subsequent European Commission regulations set maximum citrinin limits for red yeast rice food supplements. These standards pushed compliant EU market products toward tested, documented manufacturing — but the broader international supplement market has had inconsistent standards for both citrinin and monacolin K testing and labeling.

What the 2024 Kobayashi recall investigation found

The Kobayashi recall raised a complication that straightforward citrinin framing cannot explain. Company testing of the recalled products reportedly showed citrinin levels below detection limits — which meant the compound or compounds responsible for the reported renal injuries in consumers were not citrinin. The investigation pointed toward the possibility of uncharacterized secondary metabolites produced during the specific Monascus fermentation conditions used in that manufacturer’s process.

As of the conclusion of the initial investigation period, the exact causative compound or compounds had not been definitively identified in public regulatory reporting. Various uncharacterized Monascus secondary metabolites were proposed as candidates by Japanese food science researchers following the incident, but no regulatory body issued a definitive causal assignment during the investigation window covered by public records. What the case demonstrated clearly: citrinin is not the only safety-relevant secondary metabolite in Monascus fermentation; a specific producer’s process can generate unexpected metabolite profiles; and standard commercial testing focused primarily on monacolins and citrinin is not sufficient to characterize the full secondary metabolite output of every manufacturing approach.

The Consumer Affairs Agency responded by suspending new functional food registrations using beni-koji as an ingredient and initiating a broader review of the 機能性表示食品 (Functional Nutrition Foods) system that had allowed cholesterol-related structure/function claims on supplement-form beni-koji products. The regulatory gap exposed — the absence of comprehensive secondary metabolite safety assessment before registration — became a focus of the policy response.

How Japan, the US, and the EU draw different regulatory lines

The three major markets approach red yeast rice differently, and understanding those differences explains why the same ingredient can carry different claims, dose restrictions, and legal treatments across regulatory frameworks.

Japan: Before 2024, several beni-koji products were registered under the 機能性表示食品 system with cholesterol-related claims supported by systematic review of existing research. Post-recall, the Consumer Affairs Agency suspended new beni-koji registrations and signaled revision of ingredient safety standards. The incident exposed a structural gap: the registration system had not required comprehensive secondary metabolite profiling of each manufacturer’s specific fermentation output before market approval.

United States: The FDA’s position on red yeast rice supplements containing significant monacolin K dates to the late 1990s, when the agency issued warning letters to manufacturers — including Pharmanex for marketing a product called Cholestin — on the grounds that products containing a compound identical to the active ingredient in an approved drug are subject to drug regulation regardless of labeling. Compliant US products often state low or undetectable monacolin K, but because labeling is not required to specify monacolin K content, and because independent laboratory testing has found substantial variability between marketed products and their label claims, consumers cannot reliably verify what they are purchasing.

European Union: Following EFSA scientific opinions — including a 2018 assessment raising concern about statin-class adverse effects at doses providing 3 mg or more monacolin K per day — the European Commission implemented regulations setting a maximum of 3 mg monacolin K per daily serving in food supplements, alongside mandatory safety warnings about contraindications and drug interactions. EFSA had already addressed citrinin through its 2012 opinion. EU-compliant products on current markets represent a lower and bounded monacolin K exposure than pre-regulation products, though 3 mg per day is itself pharmacologically active in some individuals.

Traditional fermented food versus supplement-grade concentrates

The regulatory and clinical evidence above concerns supplement-grade concentrated extracts, not traditional fermented food applications. The distinction is worth stating directly because coverage of the 2024 recall often treated beni-koji as uniformly concerning regardless of form, and marketing overstates the equivalence in the other direction.

Okinawan tofuyo (豆腐餻) — one of the most recognizable traditional beni-koji applications in Japan — is fermented tofu made by curing tofu cubes in a paste of beni-koji, awamori (Okinawa rice spirits), and salt over an extended aging period. The beni-koji functions as a colorant and fermentation agent, giving the tofu its characteristic red coloration and complex fermented flavor. At typical serving sizes — tofuyo is eaten in small quantities as a condiment or side dish — the monacolin K exposure is a small fraction of a milligram, far below the doses studied in RCTs and below the levels that generate regulatory concern. Chinese red braised pork (hong shao rou) and char siu preparations that use red yeast rice as a natural colorant in sauce represent similarly small exposures.

Whether these traditional dietary exposures produce measurable HMG-CoA reductase effects has not been studied directly, and the dose difference from supplement RCTs suggests they would not produce the same LDL-associated marker changes. What the traditional fermented food form represents is a different entry point — culinary, cultural, and consistent with the broader fermented-food dietary context of traditional East Asian eating patterns — rather than a pharmaceutical-equivalent intervention. The sake kasu article (covered here) and the nukazuke fermentation article illustrate how other traditional fermented foods sit within that context with compound profiles entirely distinct from monacolins.

Sourcing beni-koji in culinary form

For those interested in traditional beni-koji applications rather than supplement form, food-grade red yeast rice is available for culinary use. Culinary red yeast rice powder on Amazon returns food-grade products used as natural colorants in cooking — the traditional application in Chinese braised meat, festive rice preparations, and related dishes. These are sold and used as food ingredients, not as concentrated extracts.

For broader grounding in the fermented food traditions that include beni-koji alongside standard koji, miso, and sake fermentation, Japanese fermentation guides on Amazon includes texts covering the full context within which beni-koji developed as a food ingredient over centuries.

For Okinawan cuisine specifically — including the tofuyo preparation that represents beni-koji’s most distinctive Japanese food application — Okinawan cuisine cookbooks on Amazon covers the dietary traditions of Japan’s centenarian-dense prefecture within which fermented beni-koji foods appear alongside a broader pattern of miso, sea vegetables, and traditional fermented staples.

Who should not use beni-koji supplement forms

If you are taking a prescription statin, adding a red yeast rice supplement provides a second HMG-CoA reductase inhibitor — a combination requiring physician oversight for appropriate dosing and adverse effect monitoring. The adverse effect profile of monacolin K is the statin adverse effect profile: myopathy risk, elevated liver enzyme associations, and drug interactions via CYP3A4 metabolism. That profile applies whether the compound arrives via prescription or dietary supplement.

The standard contraindications for statin use — including liver disease, pregnancy, and concurrent use of specific drug classes — apply to red yeast rice supplement use containing significant monacolin K for the same mechanistic reason.

The 2024 Kobayashi recall adds a third consideration beyond monacolins and citrinin: a specific manufacturer’s fermentation process may produce uncharacterized secondary metabolites not captured by standard product testing. For anyone with existing kidney conditions, this uncertainty is a reason for particular caution with supplement-form products, regardless of whether a given product passes citrinin testing.

Across all of this, the evidence that traditional beni-koji food use — at the amounts consumed in Okinawan cuisine or Chinese cooking applications — carries the same risks as supplement-grade concentrates is not established. The distinction is not that one is natural and therefore safe. The distinction is that the exposure is different: different monacolin K dose, different secondary metabolite concentration, different regulatory oversight for the manufacturing process. That difference matters for how you think about risk, not as a claim that traditional food use requires no consideration.

Anyone managing cholesterol markers, kidney or liver conditions, cardiovascular health, or any prescription medication should discuss both traditional beni-koji food use and any consideration of red yeast rice supplement products with a qualified healthcare professional before making changes.

---

Related: Koji Fermentation Foundation, Sake Kasu and Fermentation Peptides, Nukazuke and the Microbiome